All PlansPrior AuthHigh impact
Atezolizumab (Tecentriq®)
BCBS Tennessee·Oncology, Hematology·Medical Policy
Effective date
Jun 30, 2026
We identified it
Jun 17, 2026
Summary
This is a new comprehensive medical policy for Atezolizumab (Tecentriq®) covering multiple cancer indications including lung cancer, hepatocellular carcinoma, melanoma, and others. The policy establishes prior authorization requirements, coverage criteria, and required documentation for each indication.
Action Required
Before June 30, 2026: Billing team must implement prior authorization requirements for all Atezolizumab (Tecentriq®) claims. Update billing system to flag cases requiring PD-L1 tumor expression tests, BRAF V600 mutation tests, and EGFR/ALK testing documentation where applicable. Train staff on coverage criteria for each cancer indication and 6-month authorization limits. Claims without proper prior authorization and required test documentation will be denied.